Acute Frailty

The standing claim

In acute frailty, outcome is decided less by what is done than by how early a specialist does it — and, upstream of the hospital entirely, by whether a health system funds frailty care in the community before the crisis. The value-added-time equation is won or lost in the first hours of an admission, and lost again wherever there is no community structure to prevent the admission at all.

Where practice stands

The deconditioning clock starts at the front door. The adverse effects of immobility can begin within hours of arrival in urgent care, presenting as a multi-systemic syndrome of delirium, healthcare-associated infection, new incontinence and falls — not the slow product of a long stay (Arun & Lewis, Clinical Medicine, 2026). National analysis finds around a third of older people with frailty experience functional decline during a hospital stay.

England has, on paper, a detailed model of good front-door care — but it is largely best-practice recommendation, not contractual mandate, and delivery lags it. The NHS England Model Acute Pathway (with the RCP, Society for Acute Medicine and BGS) states patients over 65 should be assessed within 30 minutes of arrival using the Clinical Frailty Scale and the 4AT; that those with frailty (CFS 5+) should have access to a senior clinical decision-maker within 1 hour of referral in the day (or before 10am if referred overnight); and review by a consultant-level expert within 6 hours (day) or 14 hours (overnight). These are quality standards — “should”, not enforced targets. The single firm, contractual urgent-care standard touching this group is the four-hour A&E target.

Read precisely, the English front-door evidence is promising but thin: a single-centre service evaluation of an emergency-department acute frailty service (5,717 eligible presentations at CFS ≥ 6, of which only 8.1% were reviewed) found the reviewed group had a shorter mean length of stay (~2.0 vs 4.4 days), lower odds of admission (OR 0.14, 95% CI 0.087–0.231), admission avoided in 23%, and no in-hospital deaths among those reviewed (Zhang et al., 2026). This is observational, feasibility-grade evidence from one site with selective coverage — it shows what the model can do, not that it reliably does it.

What good looks like

We define “good” by the outcome that matters to the patient — being alive and in their own home — and then ask which models deliver it, judged on evidence rather than reputation.

The outcome is achievable at the highest grade of evidence. A Cochrane review of comprehensive geriatric assessment (CGA) — 29 randomised trials, 13,766 participants — found high-certainty evidence that CGA on admission increases the likelihood of being alive and in one’s own home at 3–12 months (RR 1.06, 95% CI 1.01–1.10) and reduces nursing-home admission (RR 0.80, 0.72–0.89), with no difference in mortality (Ellis et al., 2017); the earlier emergency-admission meta-analysis suggests dedicated CGA wards outperform mobile teams (Ellis et al., 2011).

The UK standards consensus converges on the same sequence — identify early → start CGA → keep moving → home first. NICE has no standalone frailty guideline, but quality standard QS136 sets the anchor: older people with complex needs should have a CGA started on admission. The GIRFT–BGS Six Steps to Better Care (2023) operationalises it, and GIRFT estimates that reducing bed-days for older people with frailty by 30% could yield up to £687m in gross savings. BGS Silver Book II frames the first 72 hours of urgent care and proposes CGA within that window.

The best-evidenced operational model is chosen on data, not fame. The most robustly quantified front-door model internationally is Australia’s nurse-led, physician-championed GEDI service (a pragmatic pre-post trial, n = 44,983 aged 70+): during operating hours it raised the likelihood of discharge (HR 1.19, 1.13–1.24), shortened ED length of stay, cut hospital length of stay and cost, and did not increase mortality or re-presentation (Wallis, Marsden et al., 2018). It is an exemplar because of its outcomes, not its profile.

System-level comparators sit upstream. Several health systems fund frailty care before the acute crisis in ways the NHS largely does not: Japan’s Long-Term Care Insurance (municipal, needs-assessed, covering roughly one in five people aged 65+) with its community-based integrated care model; Germany’s statutory long-term-care insurance with a cash-for-care allowance that underwrites home-based support; and the Nordic municipal model, where Denmark made reablement the mandatory first offer before standard home care. These are offered as structural comparators for keeping frailty care upstream — with the honest caveat that reablement’s outcome evidence is mixed (cost-neutral to modestly positive; some studies show increased downstream care), so the model is promising in design rather than proven in magnitude. Whether any of these transfers to a specific, highly deprived population is the question that decides their relevance — not their international reputation.

Through the lenses

The measure here is use value — what the encounter does to the person — not exchange value (the bed-day, the activity unit, the institutional metric). CGA’s primary outcome, alive and in your own home, is itself a value-added-time measure; the lever that moves it is time-to-specialist. Across the five domains this is the clearest instance of the recurring pattern that earlier specialist input changes trajectories — and the international comparison adds a second axis: not just earlier in the admission, but earlier than the admission, a systems-design question the NHS’s acute-centric model leaves largely unanswered.

Confidence and limits

The grades differ and are held apart deliberately. CGA rests on high-certainty international RCT evidence. The English front-door ED model is observational/feasibility-grade. The UK “standards” are mostly best-practice recommendations, not mandates. Two honest cautions: extended post-discharge home exercise produced no benefit on physical quality of life and was not cost-effective in a 15-site randomised trial (HERO; Prescott et al., 2026) — more input is not automatically better; and the international reablement evidence is genuinely mixed. The structural models are sound in design; the magnitude of their benefit, and their transferability, are not settled.

What we are watching

Randomised evidence for emergency-department CGA in the NHS (the gap the front-door evaluations expose); whether the Model Acute Pathway ambitions acquire funding or contractual force; and whether investment moves upstream toward community-anchored models, assessed on outcomes for this population rather than on which system is best known.